Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
31
RAFA Quote, Financials, Valuation and Earnings
Last price:
$0.0300
Seasonality move
:
-4.21%
Day range:
$0.0300 - $0.0350
52-week range:
$0.0300 - $0.1790
Dividend yield:
0%
P/E ratio:
14.12x
P/S ratio:
0.29x
P/B ratio:
0.24x
Volume:
110K
Avg. volume:
18.8K
1-year change:
-60%
Market cap:
$2.5M
Revenue:
$9.1M
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Rafarma Pharmaceuticals, Inc. has -- downside to fair value with a price target of -- per share.
RAFA vs. S&P 500
-
Over the past 5 trading days, Rafarma Pharmaceuticals, Inc. has underperformed the S&P 500 by -9.08% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Rafarma Pharmaceuticals, Inc. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Rafarma Pharmaceuticals, Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Rafarma Pharmaceuticals, Inc. reported revenues of --.
Earnings Growth
-
Rafarma Pharmaceuticals, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Rafarma Pharmaceuticals, Inc. reported earnings per share of --.
Enterprise value:
2.5M
EV / Invested capital:
--
Price / LTM sales:
0.29x
EV / EBIT:
5.38x
EV / Revenue:
0.27x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-17.89x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
5.38x
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $60M | $26.9M | $9.1M | $220K | $278K | |
| Gross Profit | $22.4M | $10.2M | $720K | $73K | $119K | |
| Operating Income | $6.5M | $1.9M | $456K | $31K | $82K | |
| EBITDA | $6.5M | $1.9M | $456K | $31K | $82K | |
| Diluted EPS | $0.06 | $0.01 | $0.00 | $0.00 | $0.00 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $46.8M | $46.2M | $2M | $1.8M | |
| Total Assets | -- | $81.6M | $87.3M | $12.2M | $12M | |
| Current Liabilities | -- | $15.7M | $13.8M | $1.7M | $1.6M | |
| Total Liabilities | -- | $17.7M | $16.2M | $1.7M | $1.6M | |
| Total Equity | -- | $63.9M | $71.1M | $10.5M | $10.4M | |
| Total Debt | -- | $449K | $459K | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $14.8M | -- | -$137K | $180K | -$1K | |
| Cash From Investing | -$7.7M | -- | $1K | $2K | $1K | |
| Cash From Financing | -$1.9M | -- | -$50K | -- | -- | |
| Free Cash Flow | $3.8M | -- | -$137K | $180K | -$1K | |
RAFA
Sector
Market Cap
$2.5M
--
Price % of 52-Week High
16.76%
--
Dividend Yield
0%
--
Shareholder Yield
--
--
1-Year Price Total Return
-60%
--
Beta (5-Year)
0.502
--
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.0363
200-day SMA
Sell
Level
$0.0756
Bollinger Bands (100)
Sell
Level
0.0308 - 0.0708
Chaikin Money Flow
Sell
Level
-193.1K
20-day SMA
Sell
Level
$0.0367
Relative Strength Index (RSI14)
Sell
Level
38.8729
ADX Line
Sell
Level
3.1429
Williams %R
Buy
Level
-100
50-day SMA
Sell
Level
$0.0372
MACD (12, 26)
Buy
Level
0.0060
25-day Aroon Oscillator
Sell
Level
-92
On Balance Volume
Sell
Level
-193.1K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.2837)
Buy
CA Score
(Annual)
Level (1.6496)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-0.1045)
Buy
Piotroski F Score
(Annual)
Level (7)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Rafarma Pharmaceuticals, Inc. engages in the manufacture and marketing of pharmaceutical goods. It produces all types of medical drugs in all delivery methods for various pharmacological groups. The company was founded in 1930 and is headquartered in Draper, UT.
Stock Forecast FAQ
In the current month, RAFA has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The RAFA average analyst price target in the past 3 months is --.
-
Where Will Rafarma Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Rafarma Pharmaceuticals, Inc. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Rafarma Pharmaceuticals, Inc.?
Analysts are divided on their view about Rafarma Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Rafarma Pharmaceuticals, Inc. is a Sell and believe this share price will rise from its current level to --.
-
What Is Rafarma Pharmaceuticals, Inc.'s Price Target?
The price target for Rafarma Pharmaceuticals, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is RAFA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Rafarma Pharmaceuticals, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of RAFA?
You can purchase shares of Rafarma Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Rafarma Pharmaceuticals, Inc. shares.
-
What Is The Rafarma Pharmaceuticals, Inc. Share Price Today?
Rafarma Pharmaceuticals, Inc. was last trading at $0.0300 per share. This represents the most recent stock quote for Rafarma Pharmaceuticals, Inc.. Yesterday, Rafarma Pharmaceuticals, Inc. closed at $0.0300 per share.
-
How To Buy Rafarma Pharmaceuticals, Inc. Stock Online?
In order to purchase Rafarma Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get RAFA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
RAFA
Sector
P/E ratio
14.12x
--
PEG ratio
--
--
P/B ratio
0.24x
--
Price / LTM sales
0.29x
--
Growth Metrics
RAFA
Sector
Revenue growth
--
--
Earnings growth
--
--
Revenue (5-year growth)
-4.52%
--
Earnings forecast
--
--
Profitability
RAFA
Sector
Profitability FY 2024
$674K
--
Return on invested capital
--
--
Return on assets
--
--
Return on equity
--
--
Earnings Date
Last Earnings Date
Dec
21
Next Earnings Date
Dec
21
Estimated Next Earnings Date
Mar
22
Balance Sheet
RAFA
Sector
Total cash
--
--
Short term investments
--
--
Total assets
$12M
--
Long term debt
--
--
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
